Umeå University's logo

umu.sePublications
Change search
Link to record
Permanent link

Direct link
Hernell, Olle
Alternative names
Publications (10 of 230) Show all publications
Fleming, S. A., Reyes, S. M., Donovan, S. M., Hernell, O., Jiang, R., Lönnerdal, B., . . . Wallingford, J. C. (2024). An expert panel on the adequacy of safety data and physiological roles of dietary bovine osteopontin in infancy. Frontiers in Nutrition, 11, Article ID 1404303.
Open this publication in new window or tab >>An expert panel on the adequacy of safety data and physiological roles of dietary bovine osteopontin in infancy
Show others...
2024 (English)In: Frontiers in Nutrition, E-ISSN 2296-861X, Vol. 11, article id 1404303Article, review/survey (Refereed) Published
Abstract [en]

Human milk, due to its unique composition, is the optimal standard for infant nutrition. Osteopontin (OPN) is abundant in human milk but not bovine milk. The addition of bovine milk osteopontin (bmOPN) to formula may replicate OPN’s concentration and function in human milk. To address safety concerns, we convened an expert panel to assess the adequacy of safety data and physiological roles of dietary bmOPN in infancy. The exposure of breastfed infants to human milk OPN (hmOPN) has been well-characterized and decreases markedly over the first 6 months of lactation. Dietary bmOPN is resistant to gastric and intestinal digestion, absorbed and cleared from circulation within 8–24 h, and represents a small portion (<5%) of total plasma OPN. Label studies on hmOPN suggest that after 3 h, intact or digested OPN is absorbed into carcass (62%), small intestine (23%), stomach (5%), and small intestinal perfusate (4%), with <2% each found in the cecum, liver, brain, heart, and spleen. Although the results are heterogenous with respect to bmOPN’s physiologic impact, no adverse impacts have been reported across growth, gastrointestinal, immune, or brain-related outcomes. Recombinant bovine and human forms demonstrate similar absorption in plasma as bmOPN, as well as effects on cognition and immunity. The panel recommended prioritization of trials measuring a comprehensive set of clinically relevant outcomes on immunity and cognition to confirm the safety of bmOPN over that of further research on its absorption, distribution, metabolism, and excretion. This review offers expert consensus on the adequacy of data available to assess the safety of bmOPN for use in infant formula, aiding evidence-based decisions on the formulation of infant formula.

Place, publisher, year, edition, pages
Frontiers Media S.A., 2024
Keywords
gastrointestinal, immunity, infant, milk, neurodevelopment, osteopontin, safety
National Category
Nutrition and Dietetics Pediatrics
Identifiers
urn:nbn:se:umu:diva-227573 (URN)10.3389/fnut.2024.1404303 (DOI)2-s2.0-85196853404 (Scopus ID)
Available from: 2024-07-02 Created: 2024-07-02 Last updated: 2024-07-02Bibliographically approved
Tinghäll Nilsson, U., Lönnerdal, B., Hernell, O., Kvistgaard, A. S., Jacobsen, L. N. & Karlsland Åkeson, P. (2024). Low-protein infant formula enriched with Alpha-lactalbumin during early infancy may reduce insulin resistance at 12 months: a follow-up of a randomized controlled trial. Nutrients, 16(7), Article ID 1026.
Open this publication in new window or tab >>Low-protein infant formula enriched with Alpha-lactalbumin during early infancy may reduce insulin resistance at 12 months: a follow-up of a randomized controlled trial
Show others...
2024 (English)In: Nutrients, E-ISSN 2072-6643, Vol. 16, no 7, article id 1026Article in journal (Refereed) Published
Abstract [en]

High protein intake during infancy results in accelerated early weight gain and potentially later obesity. The aim of this follow-up study at 12 months was to evaluate if modified low-protein formulas fed during early infancy have long-term effects on growth and metabolism. In a double-blinded RCT, the ALFoNS study, 245 healthy-term infants received low-protein formulas with either alpha-lactalbumin-enriched whey (α-lac-EW; 1.75 g protein/100 kcal), casein glycomacropeptide-reduced whey (CGMP-RW; 1.76 g protein/100 kcal), or standard infant formula (SF; 2.2 g protein/100 kcal) between 2 and 6 months of age. Breastfed (BF) infants served as a reference. At 12 months, anthropometrics and dietary intake were assessed, and serum was analyzed for insulin, C-peptide, and insulin-like growth factor 1 (IGF-1). Weight gain between 6 and 12 months and BMI at 12 months were higher in the SF than in the BF infants (p = 0.019; p < 0.001, respectively), but were not significantly different between the low-protein formula groups and the BF group. S-insulin and C-peptide were higher in the SF than in the BF group (p < 0.001; p = 0.003, respectively), but more alike in the low-protein formula groups and the BF group. Serum IGF-1 at 12 months was similar in all study groups. Conclusion: Feeding modified low-protein formula during early infancy seems to reduce insulin resistance, resulting in more similar growth, serum insulin, and C-peptide concentrations to BF infants at 6-months post intervention. Feeding modified low-protein formula during early infancy results in more similar growth, serum insulin, and C-peptide concentrations to BF infants 6-months post intervention, probably due to reduced insulin resistance in the low-protein groups.

Place, publisher, year, edition, pages
MDPI, 2024
Keywords
alpha-lactalbumin, body mass index, CGMP, childhood obesity, IGF-1, infant formula, infant growth, infant nutrition, insulin, low-protein
National Category
Nutrition and Dietetics Pediatrics
Identifiers
urn:nbn:se:umu:diva-223643 (URN)10.3390/nu16071026 (DOI)001201557500001 ()38613059 (PubMedID)2-s2.0-85190492425 (Scopus ID)
Available from: 2024-04-24 Created: 2024-04-24 Last updated: 2024-04-24Bibliographically approved
Björmsjö, M., Ekström, N., Silfverdal, S. A., Hernell, O., Lönnerdal, B. & Berglund, S. K. (2024). Vaccine response was higher in formula-fed infants compared to breastfed but not affected by lactoferrin or iron in a randomised controlled trial. Acta Paediatrica
Open this publication in new window or tab >>Vaccine response was higher in formula-fed infants compared to breastfed but not affected by lactoferrin or iron in a randomised controlled trial
Show others...
2024 (English)In: Acta Paediatrica, ISSN 0803-5253, E-ISSN 1651-2227Article in journal (Refereed) Epub ahead of print
Abstract [en]

Aim: To examine how reduced iron content and added bovine lactoferrin in infant formula affect the antibody response following routine immunisation.

Methods: In this randomised controlled trial, 180 Swedish formula-fed infants received, from 6 weeks to 6 months of age, a 2 mg/L iron formula with (n = 72) or without (n = 72) bovine lactoferrin, or a control formula with 8 mg/L iron and no lactoferrin (n = 36). Another 72 infants were recruited as a breastfed reference. Serum immunoglobulin G (IgG) levels against Haemophilus influenzae type b (Hib), diphtheria and tetanus were assessed at four, six and 12 months of age.

Results: With an equal gender distribution, 180 + 72 term infants were included with a mean age of 7.0 ± 0.7 weeks. At 12 months, infants fed low iron formula showed a significantly higher geometric mean Hib IgG (1.40 μg/mL [1.07–1.83]) compared to the control formula infants (0.67 μg/mL [0.42–1.07]). For all three vaccines, breastfed infants had significantly lower IgG levels at six and 12 months of age.

Conclusion: Except for higher Hib IgG levels at 12 months in infants fed low iron formula, the interventions did not affect vaccine IgG response. Unexpectedly, breastfed infants had significantly lower vaccine IgG levels compared to formula-fed infants.

Place, publisher, year, edition, pages
John Wiley & Sons, 2024
Keywords
immunology, infant formula, iron, lactoferrin, vaccine
National Category
Pediatrics
Identifiers
urn:nbn:se:umu:diva-227824 (URN)10.1111/apa.17335 (DOI)001255461600001 ()38934330 (PubMedID)2-s2.0-85197392447 (Scopus ID)
Funder
Knut and Alice Wallenberg FoundationRegion Västerbotten
Available from: 2024-07-11 Created: 2024-07-11 Last updated: 2024-07-11
Johansson, U., Öhlund, I., Lindberg, L., Hernell, O., Lönnerdal, B., Venables, M. & Lind, T. (2023). A randomized, controlled trial of a Nordic, protein-reduced complementary diet in infants: effects on body composition, growth, biomarkers, and dietary intake at 12 and 18 months. American Journal of Clinical Nutrition, 117(6), 1219-1231
Open this publication in new window or tab >>A randomized, controlled trial of a Nordic, protein-reduced complementary diet in infants: effects on body composition, growth, biomarkers, and dietary intake at 12 and 18 months
Show others...
2023 (English)In: American Journal of Clinical Nutrition, ISSN 0002-9165, E-ISSN 1938-3207, Vol. 117, no 6, p. 1219-1231Article in journal (Refereed) Published
Abstract [en]

Background: High intake of protein and low intake of plant-based foods during complementary feeding can contribute to negative long-term health effects.

Objectives: To investigate the effects of a protein-reduced, Nordic complementary diet on body composition, growth, biomarkers, and dietary intake, compared with current Swedish dietary recommendations for infants at 12 and 18 mo.

Methods: Healthy, term infants (n = 250) were randomly allocated to either a Nordic group (NG) or a conventional group (CG). From 4 to 6 mo, NG participants received repeated exposures of Nordic taste portions. From 6 to 18 mo, NG was supplied with Nordic homemade baby food recipes, protein-reduced baby food products, and parental support. CG followed the current Swedish dietary recommendations. Measurements of body composition, anthropometry, biomarkers, and dietary intake were collected from baseline and at 12 and 18 mo.

Results: Of the 250 infants, 82% (n = 206) completed the study. There were no group differences in body composition or growth. In NG, protein intake, blood urea nitrogen and plasma IGF-1 were lower compared to CG at 12 and 18 mo. Infants in NG consumed 42% to 45% more fruits and vegetables compared to CG at 12 and 18 mo, which was reflected in a higher plasma folate at 12 and 18 mo. There were no between-group differences in EI or iron status.

Conclusions: Introduction of a predominantly plant-based, protein-reduced diet as part of complementary feeding is feasible and can increase fruit and vegetable intake.

This trial was registered at clinicaltrials.gov as NCT02634749.

Place, publisher, year, edition, pages
Elsevier, 2023
Keywords
complementary feeding, early nutrition, fruit, infancy, infant feeding, Nordic diet, plant-based food, repeated exposure, vegetables
National Category
Nutrition and Dietetics
Identifiers
urn:nbn:se:umu:diva-206971 (URN)10.1016/j.ajcnut.2023.03.020 (DOI)001015232200001 ()36990225 (PubMedID)2-s2.0-85152423063 (Scopus ID)
Funder
Region Västerbotten, VLL-644531Region Västerbotten, VLL-488901Region Västerbotten, VLL-677921Region Västerbotten, VLL-761381Umeå University
Available from: 2023-04-24 Created: 2023-04-24 Last updated: 2023-09-05Bibliographically approved
Lindquist, S., Wang, Y., Andersson, E.-L., Tsuji Grebe, S., Alenius, G.-M., Rantapää-Dahlqvist, S., . . . Hernell, O. (2023). Effects of bile salt-stimulated lipase on blood cells and associations with disease activity in human inflammatory joint disorders. PLOS ONE, 18(8), Article ID e0289980.
Open this publication in new window or tab >>Effects of bile salt-stimulated lipase on blood cells and associations with disease activity in human inflammatory joint disorders
Show others...
2023 (English)In: PLOS ONE, E-ISSN 1932-6203, Vol. 18, no 8, article id e0289980Article in journal (Refereed) Published
Abstract [en]

The bile salt-stimulated lipase (BSSL) was originally recognized as a lipolytic enzyme expressed by the exocrine pancreas and in some species, notably humans, the lactating mammary gland, being secreted into the duodenum and with the mother’s milk, respectively. However, BSSL is also present in the blood and has been assigned additional functions, even beyond the gastrointestinal tract. Conventional BSSL knockout mice are protected from developing disease in animal models of arthritis, and antibodies directed towards BSSL prevent or mitigate disease in similar models. The aim of this study was to investigate the role of BSSL as a newly discovered player in inflammation and specifically in inflammatory joint disorders. As part of mechanism of action, we here show that BSSL is secreted by neutrophils, interacts with monocytes and stimulates their migration in vitro. An anti-BSSL antibody that blocks the human BSSL-monocyte interaction was shown to simultaneously prevent the signaling pathway by which BSSL induce cell migration. Moreover, in this cohort study we show that BSSL levels are significantly higher in blood samples from patients with rheumatoid arthritis and psoriatic arthritis compared to healthy controls. The BSSL levels in patients’ blood also correlated with disease activity scores and established inflammatory markers. Hence, although the mode of action is not yet fully clarified, we conclude that BSSL could be considered a proinflammatory component in the innate immune system and thus a possible novel target for treatment of chronic inflammation.

Place, publisher, year, edition, pages
Public Library of Science (PLoS), 2023
National Category
Medicinal Chemistry
Identifiers
urn:nbn:se:umu:diva-214042 (URN)10.1371/journal.pone.0289980 (DOI)001051705700041 ()37566600 (PubMedID)2-s2.0-85167768925 (Scopus ID)
Funder
Region Västerbotten
Available from: 2023-09-06 Created: 2023-09-06 Last updated: 2023-09-06Bibliographically approved
Tinghäll Nilsson, U., Hernell, O., Lönnerdal, B., Hartvigsen, M. L., Jacobsen, L. N., Kvistgaard, A. S. & Karlsland Åkeson, P. (2023). Low-protein formulas with alpha-lactalbumin-enriched or glycomacropeptide-reduced whey: effects on growth, nutrient intake and protein metabolism during early infancy. Nutrients, 15(4), Article ID 1010.
Open this publication in new window or tab >>Low-protein formulas with alpha-lactalbumin-enriched or glycomacropeptide-reduced whey: effects on growth, nutrient intake and protein metabolism during early infancy
Show others...
2023 (English)In: Nutrients, E-ISSN 2072-6643, Vol. 15, no 4, article id 1010Article in journal (Refereed) Published
Abstract [en]

Protein intake is higher in formula-fed than in breast-fed infants during infancy, which may lead to an increased risk of being overweight. Applying alpha-lactalbumin (α-lac)-enriched whey or casein glycomacropeptide (CGMP)-reduced whey to infant formula may enable further reduction of formula protein by improving the amino acid profile. Growth, nutrient intake, and protein metabolites were evaluated in a randomized, prospective, double-blinded intervention trial where term infants received standard formula (SF:2.2 g protein/100 kcal; n = 83) or low-protein formulas with α-lac-enriched whey (α-lac-EW;1.75 g protein/100 kcal; n = 82) or CGMP-reduced whey (CGMP-RW;1.76 g protein/100 kcal; n = 80) from 2 to 6 months. Breast-fed infants (BF; n = 83) served as reference. Except between 4 and 6 months, when weight gain did not differ between α-lac-EW and BF (p = 0.16), weight gain was higher in all formula groups compared to BF. Blood urea nitrogen did not differ between low-protein formula groups and BF during intervention, but was lower than in SF. Essential amino acids were similar or higher in α-lac-EW and CGMP-RW compared to BF. Conclusion: Low-protein formulas enriched with α-lac-enriched or CGMP-reduced whey supports adequate growth, with more similar weight gain in α-lac-enriched formula group and BF, and with metabolic profiles closer to that of BF infants.

Place, publisher, year, edition, pages
MDPI, 2023
Keywords
alpha-lactalbumin, amino acids, CGMP, energetic efficiency, infant formula, infant growth, low protein, obesity, protein metabolism, protein quality
National Category
Nutrition and Dietetics
Identifiers
urn:nbn:se:umu:diva-205491 (URN)10.3390/nu15041010 (DOI)000940985900001 ()36839368 (PubMedID)2-s2.0-85148898752 (Scopus ID)
Available from: 2023-03-14 Created: 2023-03-14 Last updated: 2024-04-10Bibliographically approved
Sjödin, K. S., Sjödin, A., Ruszczyński, M., Kristensen, M. B., Hernell, O., Szajewska, H. & West, C. E. (2023). Targeting the gut-lung axis by synbiotic feeding to infants in a randomized controlled trial. BMC Biology, 21(1), Article ID 38.
Open this publication in new window or tab >>Targeting the gut-lung axis by synbiotic feeding to infants in a randomized controlled trial
Show others...
2023 (English)In: BMC Biology, E-ISSN 1741-7007, Vol. 21, no 1, article id 38Article in journal (Refereed) Published
Abstract [en]

BACKGROUND: Formula-fed infants are at increased risk of infections. Due to the cross-talk between the mucosal systems of the gastrointestinal and respiratory tracts, adding synbiotics (prebiotics and probiotics) to infant formula may prevent infections even at distant sites. Infants that were born full term and weaned from breast milk were randomized to prebiotic formula (fructo- and galactooligosaccharides) or the same prebiotic formula with Lactobacillus paracasei ssp. paracasei F19 (synbiotics) from 1 to 6 months of age. The objective was to examine the synbiotic effects on gut microbiota development. RESULTS: Fecal samples collected at ages 1, 4, 6, and 12 months were analyzed using 16S rRNA gene sequencing and a combination of untargeted gas chromatography-mass spectrometry/liquid chromatography-mass spectrometry. These analyses revealed that the synbiotic group had a lower abundance of Klebsiella, a higher abundance of Bifidobacterium breve compared to the prebiotic group, and increases in the anti-microbial metabolite d-3-phenyllactic acid. We also analyzed the fecal metagenome and antibiotic resistome in the 11 infants that had been diagnosed with lower respiratory tract infection (cases) and 11 matched controls using deep metagenomic sequencing. Cases with lower respiratory tract infection had a higher abundance of Klebsiella species and antimicrobial resistance genes related to Klebsiella pneumoniae, compared to controls. The results obtained using 16S rRNA gene amplicon and metagenomic sequencing were confirmed in silico by successful recovery of the metagenome-assembled genomes of the bacteria of interest. CONCLUSIONS: This study demonstrates the additional benefit of feeding specific synbiotics to formula-fed infants over prebiotics only. Synbiotic feeding led to the underrepresentation of Klebsiella, enrichment of bifidobacteria, and increases in microbial degradation metabolites implicated in immune signaling and in the gut-lung and gut-skin axes. Our findings support future clinical evaluation of synbiotic formula in the prevention of infections and associated antibiotic treatment as a primary outcome when breastfeeding is not feasible. TRIAL REGISTRATION: ClinicalTrials.gov NCT01625273. Retrospectively registered on 21 June 2012.

Place, publisher, year, edition, pages
BioMed Central (BMC), 2023
Keywords
Antibiotics, Bifidobacteria, Infant gut microbiota, Klebsiella, Lower respiratory tract infection, Prebiotics, Probiotics
National Category
Nutrition and Dietetics Pediatrics
Identifiers
urn:nbn:se:umu:diva-205355 (URN)10.1186/s12915-023-01531-3 (DOI)000936843800002 ()36803508 (PubMedID)2-s2.0-85148399778 (Scopus ID)
Funder
Umeå UniversityRegion VästerbottenMagnus Bergvall FoundationKnut and Alice Wallenberg FoundationSwedish Research Council
Available from: 2023-04-03 Created: 2023-04-03 Last updated: 2024-01-17Bibliographically approved
Callahan, E. A., Chatila, T., Deckelbaum, R. J., Field, C. J., Greer, F. R., Hernell, O., . . . Wallingford, J. C. (2022). Assessing the safety of bioactive ingredients in infant formula that affect the immune system: recommendations from an expert panel. American Journal of Clinical Nutrition, 115(2), 570-587
Open this publication in new window or tab >>Assessing the safety of bioactive ingredients in infant formula that affect the immune system: recommendations from an expert panel
Show others...
2022 (English)In: American Journal of Clinical Nutrition, ISSN 0002-9165, E-ISSN 1938-3207, Vol. 115, no 2, p. 570-587Article in journal (Refereed) Published
Abstract [en]

Bioactive ingredients for infant formula have been sought to reduce disparities in health outcomes between breastfed and formula-fed infants. Traditional food safety methodologies have limited ability to assess some bioactive ingredients. It is difficult to assess the effects of nutrition on the infant immune system because of coincident developmental adaptations to birth, establishment of the microbiome and introduction to solid foods, and perinatal environmental factors. An expert panel was convened to review information on immune system development published since the 2004 Institute of Medicine report on evaluating the safety of new infant formula ingredients and to recommend measurements that demonstrate the safety of bioactive ingredients intended for that use. Panel members participated in a 2-d virtual symposium in November 2020 and in follow-up discussions throughout early 2021. Key topics included identification of immune system endpoints from nutritional intervention studies, effects of human milk feeding and human milk substances on infant health outcomes, ontologic development of the infant immune system, and microbial influences on tolerance. The panel explored how "nonnormal" conditions such as preterm birth, allergy, and genetic disorders could help define developmental immune markers for healthy term infants. With consideration of breastfed infants as a reference, ensuring proper control groups, and attention to numerous potential confounders, the panel recommended a set of standard clinical endpoints including growth, response to vaccination, infection and other adverse effects related to inflammation, and allergy and atopic diseases. It compiled a set of candidate markers to characterize stereotypical patterns of immune system development during infancy, but absence of reference ranges, variability in methods and populations, and unreliability of individual markers to predict disease prevented the panel from including many markers as safety endpoints. The panel's findings and recommendations are applicable for industry, regulatory, and academic settings, and will inform safety assessments for immunomodulatory ingredients in foods besides infant formula.

Place, publisher, year, edition, pages
Oxford University Press, 2022
Keywords
bioactives, development, human milk, immune system, immunomodulation, infant, infant formula, nutrition, safety recommendations
National Category
Nutrition and Dietetics
Identifiers
urn:nbn:se:umu:diva-192642 (URN)10.1093/ajcn/nqab346 (DOI)000753585200026 ()34634105 (PubMedID)2-s2.0-85124444393 (Scopus ID)
Available from: 2022-02-22 Created: 2022-02-22 Last updated: 2023-09-05Bibliographically approved
Björmsjö, M., Hernell, O., Lönnerdal, B. & Berglund, S. (2022). Immunological Effects of Adding Bovine Lactoferrin and Reducing Iron in Infant Formula: A Randomized Controlled Trial. Journal of Pediatric Gastroenterology and Nutrition - JPGN, 74(3), e65-e72
Open this publication in new window or tab >>Immunological Effects of Adding Bovine Lactoferrin and Reducing Iron in Infant Formula: A Randomized Controlled Trial
2022 (English)In: Journal of Pediatric Gastroenterology and Nutrition - JPGN, ISSN 0277-2116, E-ISSN 1536-4801, Vol. 74, no 3, p. e65-e72Article in journal (Refereed) Published
Abstract [en]

OBJECTIVES: Compared to formula-fed infants, breastfed infants have a lower risk of infections. Two possible reasons for this are the presence of the anti-infective and anti-inflammatory protein lactoferrin and the lower level of iron in breast milk. We explored how adding bovine lactoferrin and reducing the iron concentration in infant formula affect immunology and risk of infections in healthy infants.

METHODS: In a double-blind controlled trial, term formula-fed (FF) Swedish infants (n = 180) were randomized to receive, from 6 weeks to 6 months of age, a low-iron formula (2 mg/L) with added bovine lactoferrin (1.0 g/L) (Lf+; n = 72); low-iron formula with no added lactoferrin (Lf-; n = 72); and standard formula at 8 mg/L iron and no added lactoferrin (control formula [CF]; n = 36). Cytokines, infections, and infection related treatments were assessed until 12 months of age.

RESULTS: No adverse effects were observed. There were no apparent effects on transforming growth factor beta (TGF-β)1, TGF-β2, tumor necrosis factor alfa (TNF-α) or interleukin2 (IL-2) at 4, 6, or 12 months, except of higher TGF-β2 at 6 months in the CF group in comparison to the low iron groups combined (P = 0.033). No significant differences in otitis, respiratory infections, gastroenteritis, or other monitored infections and treatments were detected for any of the study feeding groups during the first 6 months and only a few and diverging effects were observed between 6 and 12 months.

CONCLUSIONS: Adding bovine lactoferrin and reducing iron from 8 to 2 mg/L in infant formula was safe. No clinically relevant effects on cytokines or infection related morbidity were observed in this well-nourished and healthy population.

Place, publisher, year, edition, pages
Wolters Kluwer, 2022
National Category
Pediatrics Gastroenterology and Hepatology
Identifiers
urn:nbn:se:umu:diva-193008 (URN)10.1097/MPG.0000000000003367 (DOI)000761954400006 ()34908015 (PubMedID)2-s2.0-85125554033 (Scopus ID)
Funder
Knut and Alice Wallenberg FoundationThe Kempe Foundations
Available from: 2022-03-10 Created: 2022-03-10 Last updated: 2024-07-11Bibliographically approved
Lee, H., Li, Z., Christensen, B., Peng, Y., Li, X., Hernell, O., . . . Slupsky, C. M. (2022). Metabolic phenotype and microbiome of infants fed formula containing Lactobacillus paracasei strain F-19. Frontiers in Pediatrics , 10, Article ID 856951.
Open this publication in new window or tab >>Metabolic phenotype and microbiome of infants fed formula containing Lactobacillus paracasei strain F-19
Show others...
2022 (English)In: Frontiers in Pediatrics , E-ISSN 2296-2360, Vol. 10, article id 856951Article in journal (Refereed) Published
Abstract [en]

Early childhood nutrition drives the development of the gut microbiota. In contrast to breastfeeding, feeding infant formula has been shown to impact both the gut microbiota and the serum metabolome toward a more unfavorable state. It is thought that probiotics may alter the gut microbiota and hence create a more favorable metabolic outcome. To investigate the impact of supplementation with Lactobacillus paracasei spp. paracasei strain F-19 on the intestinal microbiota and the serum metabolome, infants were fed a formula containing L. paracasei F19 (F19) and compared to a cohort of infants fed the same standard formula without the probiotic (SF) and a breast-fed reference group (BF). The microbiome, as well as serum metabolome, were compared amongst groups. Consumption of L. paracasei F19 resulted in lower community diversity of the gut microbiome relative to the SF group that made it more similar to the BF group at the end of the intervention (4 months). It also significantly increased lactobacilli and tended to increase bifidobacteria, also making it more similar to the BF group. The dominant genus in the microbiome of all infants was Bifidobacterium throughout the intervention, which was maintained at 12 months. Although the serum metabolome of the F19 group was more similar to the group receiving the SF than the BF group, increases in serum TCA cycle intermediates and decreases in several amino acids in the metabolome of the F19 group were observed, which resulted in a metabolome that trended toward the BF group. Overall, L. paracasei F19 supplementation did not override the impact of formula-feeding but did impact the microbiome and the serum metabolome in a way that may mitigate some unfavorable metabolic impacts of formula-feeding.

Place, publisher, year, edition, pages
Frontiers Media S.A., 2022
Keywords
gut microbiota, infant formula, Lactobacillus, metabolome, probiotics
National Category
Pediatrics
Identifiers
urn:nbn:se:umu:diva-203143 (URN)10.3389/fped.2022.856951 (DOI)000805952600001 ()35558362 (PubMedID)2-s2.0-85132640166 (Scopus ID)
Available from: 2023-01-16 Created: 2023-01-16 Last updated: 2023-03-20Bibliographically approved
Projects
Growth and development with infant formula [2009-00209_Vinnova]; Umeå University
Organisations

Search in DiVA

Show all publications